Loading…
Immunoinformatics Insights into the Internalin A and B Proteins to Design a Multi-Epitope Subunit Vaccine for L. monocytogenes
As an important foodborne pathogen, Listeria monocytogenes is associated with high hospitalization and case-fatality rates. Outbreaks due to foods contaminated with this pathogen continue to occur globally. A suitable vaccine can protect susceptible populations against this infection. In this study,...
Saved in:
Published in: | International journal of peptide research and therapeutics 2022, Vol.28 (1), Article 47 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | As an important foodborne pathogen,
Listeria monocytogenes
is associated with high hospitalization and case-fatality rates. Outbreaks due to foods contaminated with this pathogen continue to occur globally. A suitable vaccine can protect susceptible populations against this infection. In this study, two essential surface proteins (internalins A and B) of
L. monocytogenes
which are used for the entry of bacteria into different host cells were selected as candidates for the design of a multi-epitope protein vaccine by powerful immunoinformatics servers and soft wares. Epitopes were selected based on scores of antigenic properties, cytokine induction potential and allergenicity. To construct the multi-epitope vaccine, the selected cytotoxic T lymphocytes epitopes were linked together by an AAY linker, whereas GPGPG linkers were used to link the helper T lymphocytes epitopes. Physiochemical characterization, and the secondary and tertiary structures of the protein vaccine were determined. After refinement, validation and energy minimization, the immune simulation was conducted by the C-ImmSim server. The obtained results showed that the designed vaccine is stable and could effectively trigger the immune response. Overall, the results of this study demonstrated that the designed vaccine is specific, antigenic, non-allergenic, and can effectively prevent
L. monocytogenes
infections. Further clinical trials are required to check the efficacy of this vaccine. |
---|---|
ISSN: | 1573-3149 1573-3904 |
DOI: | 10.1007/s10989-021-10359-w |